Mazdutide is a groundbreaking GLP-1 receptor and glucagon receptor (GCGR) dual agonist approved in China (June 2025) for long-term weight management .

As an oxyntomodulin analog, it delivers synergistic effects by activating both receptors: GLP-1R reduces appetite and slows gastric emptying, while GCGR boosts fat breakdown and energy expenditure . Phase III trials (GLORY-1) confirmed significant weight loss in Chinese adults, with 4mg/6mg doses outperforming placebo and favorable safety profiles .

Indicated for adults with BMI ≥28kg/m² (obesity) or ≥24kg/m² (overweight) plus weight-related comorbidities, this injectable therapy addresses unmet metabolic needs. It also shows promise in glycemic control and lipid improvement, supporting holistic metabolic health .

Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.